{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:23:34Z","timestamp":1793021014435,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ijantimicag.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T10:34:27Z","timestamp":1490092467000},"page":"554-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Old antibiotics for emerging multidrug-resistant\/extensively drug-resistant tuberculosis (MDR\/XDR-TB)"],"prefix":"10.1016","volume":"49","author":[{"given":"Philippe","family":"Brouqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Quenard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Drancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0010","series-title":"Global tuberculosis report 2016","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0015","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1378\/chest.08-2427","article-title":"Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran","volume":"136","author":"Velayati","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0020","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ijantimicag.2013.08.004","article-title":"Totally resistant tuberculosis: will antileprosy drugs be helpful?","volume":"42","author":"Brouqui","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0025","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0030","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0035","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/jac\/dku438","article-title":"Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study","volume":"70","author":"Cambau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0040","doi-asserted-by":"publisher","DOI":"10.1371\/annotation\/644591a8-8ae6-450e-974e-1cd1f08f52c7","article-title":"Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa","volume":"8","author":"Shean","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0045","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0050","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0055","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000371869","article-title":"French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS\u00ae in MDR-TB patients","volume":"60","author":"Kibleur","year":"2014","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0060","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/1471-2334-14-542","article-title":"Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss","volume":"14","author":"Modongo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0065","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/jso.24220","article-title":"Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: a prospective study on the incidence of complications and overall failures","volume":"113","author":"Bertoglio","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0070","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132543","article-title":"Loss-to-follow-up on multidrug resistant tuberculosis treatment in Gujarat, India: the WHEN and WHO of it","volume":"10","author":"Shringarpure","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0075","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150849","article-title":"\u2018When treatment is more challenging than the disease\u2019: a qualitative study of MDR-TB patient retention","volume":"11","author":"Shringarpure","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0080","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fmicb.2014.00551","article-title":"A new strategy to fight antimicrobial resistance: the revival of old antibiotics","volume":"5","author":"Cassir","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0085","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/ijms17030373","article-title":"Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review","volume":"17","author":"Sotgiu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0090","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jac\/43.5.615","article-title":"Antimycobacterial activities of riminophenazines","volume":"43","author":"Reddy","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0095","first-page":"560","article-title":"Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh","volume":"8","author":"Van Deun","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0100","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.5588\/ijtld.13.0312","article-title":"Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [correspondence]","volume":"17","author":"Yoo","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0105","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1469-0691.2011.03716.x","article-title":"Clofazimine in the treatment of multidrug-resistant tuberculosis","volume":"18","author":"Xu","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0110","doi-asserted-by":"publisher","first-page":"e004143","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0115","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0190-9622(90)70204-U","article-title":"Skin pigmentation from Clofazimine therapy in leprosy patients: a reappraisal","volume":"23","author":"Job","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0120","first-page":"470","article-title":"Sulfanilamide in clinical tuberculosis","volume":"40","author":"Nayer","year":"1939","journal-title":"Am Rev Tuberc"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0125","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1128\/AAC.01868-13","article-title":"Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study","volume":"58","author":"Hasse","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094393","article-title":"Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis patients: results from a nationwide cohort in Nigeria","volume":"9","author":"Oladimeji","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115211","article-title":"Factors associated with death during tuberculosis treatment of patients co-infected with HIV at the Yaound\u00e9 Central Hospital, Cameroon: an 8-year hospital-based retrospective cohort study (2006\u20132013)","volume":"9","author":"Agbor","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0140","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1128\/AAC.01658-08","article-title":"Tuberculosis and trimethoprim\u2013sulfamethoxazole","volume":"53","author":"Forgacs","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0145","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/jac\/dkr501","article-title":"Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan","volume":"67","author":"Huang","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0150","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1128\/AAC.00029-10","article-title":"Mycobacterium tuberculosis and sulfamethoxazole susceptibility","volume":"54","author":"Ong","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0155","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1093\/jac\/dks306","article-title":"Sulfamethoxazole enhances the antimycobacterial activity of rifampicin","volume":"67","author":"Macingwana","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0160","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10096-012-1787-3","article-title":"The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics","volume":"32","author":"Dubourg","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0165","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1183\/09031936.00114812","article-title":"Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis","volume":"42","author":"Alsaad","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0170","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1128\/AAC.01683-13","article-title":"In vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in France","volume":"57","author":"Ameen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0175","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0041-3879(80)90058-6","article-title":"In-vitro antimycobacterial activity of minocycline","volume":"61","author":"Tsukamura","year":"1980","journal-title":"Tubercle"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0180","first-page":"379","article-title":"In vitro antituberculous action of minocycline on Mycobacterium tuberculosis","volume":"58","author":"Tsukamura","year":"1983","journal-title":"Kekkaku"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0185","first-page":"665","article-title":"Combined effect of minocycline with antitubercular agents on Mycobacterium tuberculosis: in vitro study","volume":"58","author":"Tsukamura","year":"1983","journal-title":"Kekkaku"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0190","first-page":"375","article-title":"Minimal inhibitory concentrations of lomefloxacin and minocycline against drug-sensitive and drug-resistant isolates of M. tuberculosis compared on L-J and 7H11 media","volume":"65","author":"Kamala","year":"1997","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0195","first-page":"725","article-title":"Achievement of sputum culture negative conversion by minocycline in a case with extensively drug-resistant pulmonary tuberculosis","volume":"83","author":"Kawada","year":"2008","journal-title":"Kekkaku"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0200","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10096-004-1268-4","article-title":"Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy","volume":"24","author":"Balabanova","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0205","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMc1513236","article-title":"\u03b2-Lactams against tuberculosis\u2014new trick for an old dog?","volume":"375","author":"Diacon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0210","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1183\/09031936.00147014","article-title":"Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis","volume":"46","author":"van der Paardt","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0215","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1183\/09031936.00113713","article-title":"Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis","volume":"43","author":"Alsaad","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0220","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1128\/AAC.01524-10","article-title":"Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections","volume":"55","author":"Ahmad","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0225","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1086\/317524","article-title":"Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis","volume":"32","author":"Sacks","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0230","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1086\/322725","article-title":"Clinical and microbiological efficacy of adjunctive salvage therapy with inhaled aminoglycosides in a patient with refractory cavitary pulmonary tuberculosis","volume":"33","author":"Parola","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.02.008_bib0235","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1128\/AAC.02346-12","article-title":"single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis","volume":"57","author":"Dharmadhikari","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T05:53:50Z","timestamp":1535954030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0924857917300857"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.02.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Old antibiotics for emerging multidrug-resistant\/extensively drug-resistant tuberculosis (MDR\/XDR-TB)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}